Mpox

This multicenter, open-label trial is designed to compare the immunogenicity and safety of MVA-BN® vaccine in children aged 2 years to under 12 years compared to adults for the prevention of smallpox, Mpox and related orthopoxvirus infections.

Sample size is 460 participants, 230 in each age group and 10% the paediatric population should be age 2 > 6.

Primary objectives

• To assess the immunogenicity of the MVA-BN standard regimen in eliciting neutralizing antibodies against the vaccinia virus in children compared to adults.
• To assess the safety and reactogenicity of the MVA-BN standard regimen in children and adults

Country

Uganda, DRC

Status

On-going

Tentative End date

April 2026

Our Role

The Mbarara center is one of the 3 study sites. there's another site in Uganda, Uganda Virus Research Institute Clinic- Entebbe, and one in the DRC

Sponsor

Bavarian Nordic, Vaccine manufacturer.

CRO

ACE Research

Funder

CEPI (Coalition for Epidemic Preparedness Innovations)